Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Humana (HUM – Research Report), Boston Scientific (BSX – Research Report) and Biogen (BIIB – Research Report).
Humana (HUM)
In a report released today, Lisa Gill from J.P. Morgan maintained a Hold rating on Humana. The company’s shares closed last Tuesday at $327.98, close to its 52-week low of $299.23.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
Currently, the analyst consensus on Humana is a Moderate Buy with an average price target of $365.58, a 12.3% upside from current levels. In a report issued on April 15, Truist Financial also maintained a Hold rating on the stock with a $355.00 price target.
See the top stocks recommended by analysts >>
Boston Scientific (BSX)
In a report released today, Robbie Marcus from J.P. Morgan maintained a Buy rating on Boston Scientific. The company’s shares closed last Tuesday at $68.99, close to its 52-week high of $69.21.
According to TipRanks.com, Marcus is a 5-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $73.00, representing a 6.9% upside. In a report issued on April 15, BTIG also maintained a Buy rating on the stock with a $74.00 price target.
Biogen (BIIB)
In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Biogen. The company’s shares closed last Tuesday at $193.18, close to its 52-week low of $189.44.
According to TipRanks.com, Schott is a 3-star analyst with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $287.76, implying a 48.8% upside from current levels. In a report issued on April 12, Bank of America Securities also maintained a Hold rating on the stock with a $260.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HUM:
- Humana Inc Reveals Quarterly Financial Performance and Projections
- Humana expands use of Cohere Health’s authorization platform
- Jefferies says Cigna acquisition of Humana ‘seems plausible’ near $420 per share
- Is HUM a Buy, Before Earnings?
- Hospital survey weakened ‘dramatically’ in March, says TD Cowen
